Agree. I hate to give examples here but, Dendreon comes to mind. Dendreon had so must anticipated revenue growth, and that's what propelled it to $57.00 a share on approval. Hopefully, the forward earning that are placed on ACT by people are not too extravagant. Hell, I would settle for 10 x forward. So, yes they can make it but, can they sell it? Remember when Rabin said they were inundated with volunteers for the trials? What does that tell you? Let's hope that ACT doesn't become too greedy upon approval and fall into the same situation that Dendreon has.
Market Data 
Markets 
AI
